Quality by Design Approach for the Development and Validation of Glipizide, an Antidiabetic Drug, by RP-UPLC with Application to Formulated Forms and Urine

Table 1

Screening: summary of method selection*.

S. no.	Column	Observations	Remarks
1	Acquity BEH C8 (100 × 2.1) mm, 1.7 µm	Asymmetrical peak with fronting and tailing	Not satisfactory
2	Acquity BEH C18 (100 × 2.1) mm, 1.7 µm	Asymmetrical peak with tailing	Not satisfactory
3	Acquity HSS cyano (50 × 2.1) mm, 1.7 µm	Split peak	Not satisfactory
4	Acquity HSS BEH shield RP18 (50 × 2.1) mm, 1.7 µm	Asymmetrical peak	Not satisfactory
5	Zorbax Extend C-18 (50 × 4.6) mm, 1.8 µm	Symmetrical peak	satisfactory

 *By keeping one column constant, the mobile phase, temperature, buffer, and sample concentration parameters were changed.